Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Monday 31 March, 2014

AstraZeneca PLC

Director/PDMR Shareholding

RNS Number : 5979D
AstraZeneca PLC
31 March 2014
 



Transaction by Person Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

 

On 28 March 2014, Marc Dunoyer, a Director of AstraZeneca PLC, was granted awards over the Company's ordinary shares under the terms of the AstraZeneca Investment Plan (AZIP), the AstraZeneca Performance Share Plan (AZPSP) and the AstraZeneca Deferred Bonus Plan (AZDBP) as detailed below.

 

 

Name

Shares awarded under AZIP

Shares awarded under AZPSP

Shares awarded under AZDBP

Award price per share

 

Marc Dunoyer

 

8,709

 

52,254

 

2,679

 

3904p

 

The AZIP award is subject to a four-year performance period (1 January 2014 to 31 December 2017) and a subsequent four-year holding period (1 January 2018 to 31 December 2021).

 

The AZPSP award is subject to a three-year performance period (1 January 2014 to 31 December 2016).

 

The AZDBP award is subject to a three-year holding period (28 March 2014 to 27 March 2017).

 

A summary of these plans and information about the performance measures that relate to the AZIP and AZPSP awards is set out in the Directors' Remuneration Report in the AstraZeneca Annual Report and Form 20-F Information 2013 which is available on the Company's website www.astrazeneca.com.

 

As a result of these awards, Mr Dunoyer has an interest in 228,676 ordinary shares which represents approximately 0.02% of the Company's issued ordinary capital.

 

 

A C N Kemp

Company Secretary

31 March 2014

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUARURSRAOOAR

a d v e r t i s e m e n t